• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

    5/14/25 4:30:00 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTOR alert in real time by email

    CRANFORD, N.J., May 14, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal second quarter ended March 31, 2025.

    Citius Oncology logo (PRNewsfoto/Citius Oncology, Inc.)

    "In Q2 2025, Citius Oncology advanced its transformation from a development-stage company to a commercial-stage organization. Following FDA approval of LYMPHIR, we intensified our focus on disciplined capital deployment and operational execution to support the success of our planned U.S. launch," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals.

    "This quarter's progress underscores our commitment to creating long-term value by ensuring LYMPHIR reaches patients with cutaneous T-cell lymphoma. Discussions with prospective commercial and strategic partners are underway as we concurrently pursue opportunities to secure additional capital to enhance our financial flexibility. These efforts are critical as we lay the foundation for sustained commercial success. With disciplined execution and a focused strategic vision, we believe Citius Oncology is poised to deliver meaningful near-term impact and durable shareholder value," concluded Mazur.

    FISCAL SECOND QUARTER 2025 FINANCIAL RESULTS:

    Liquidity

    Citius Oncology is a subsidiary of Citius Pharma. Citius Pharma plans to continue to fund Citius Oncology until Citius Oncology raises adequate capital through equity financings from outside investors and/or generates revenue from the future sales of LYMPHIR. Citius Oncology has also retained Jefferies LLC as exclusive financial advisor to evaluate strategic alternatives aimed at maximizing stockholder value.

    As of March 31, 2025, the Company had $112 in cash and cash equivalents and 71,552,402 common shares outstanding. Citius Oncology will need to secure additional capital to support operations beyond May 2025.

    Research and Development (R&D) Expenses  

    R&D expenses were $3.1 million for the quarter ended March 31, 2025, as compared to $1.3 million for the quarter ended March 31, 2024. For the six months ended March 31, 2025, R&D expenses were $4.4 million, as compared to $2.5 million for the six months ended March 31, 2024. The increase is primarily related to costs associated with the expense of a drug substance batch needed for the pre-license inspection of the manufacturer.

    General and Administrative (G&A) Expenses

    G&A expenses were $2.2 million for the quarter ended March 31, 2025, as compared to $1.4 million for the quarter ended March 31, 2024. For the six months ended March 31, 2025, G&A expenses were $5.5 million, as compared to $2.9 million for the six months ended March 31, 2024. The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers.

    Stock-based Compensation Expense

    For the quarter ended March 31, 2025, stock-based compensation expense was $2.1 million, as compared to $2.0 million for the quarter ended March 31, 2024. For the six months ended March 31, 2025, stock-based compensation expense was $3.9 million, as compared to $3.9 million for the six months ended March 31, 2024. The increase was primarily due to new options granted in December 2024.

    Net loss

    Net loss was $7.7 million, or ($0.11) per share, for the quarter ended March 31, 2025, as compared to a net loss of $4.8 million, or ($0.07) per share, for the quarter ended March 31, 2024. Net loss for the six months ended March 31, 2025 was $14.4 million, as compared to a net loss of $9.6 million for the six months ended March 31, 2024. The increase in net loss was primarily due to the increase in our operating expenses.

    About Citius Oncology, Inc.

    Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com

    Forward-Looking Statements

    This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.  Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our need for substantial additional funds and our ability to raise additional money to fund our operations beyond May 2025 and for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR, including covering the costs of licensing payments, product manufacturing and other third-party goods and services,  and any of our other product candidates that may be approved by the FDA; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; the estimated markets for our product candidates and the acceptance thereof by any market; our ability to regain compliance with Nasdaq's continued listing standards; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024, filed with the SEC on December 27, 2024, as amended on January 27, 2025, Citius Oncology's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 14, 2025, and as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

    Investor Contact:

    Ilanit Allen

    [email protected]

    908-967-6677 x113

    Media Contact:

    STiR-communications

    Greg Salsburg

    [email protected] 

    -- Financial Tables Follow –

     

    CITIUS ONCOLOGY, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Unaudited)



















    March 31,

    2025





    September 30,

    2024



    Current Assets:













    Cash and cash equivalents



    $

    112





    $

    112



    Inventory





    15,339,253







    8,268,766



    Prepaid expenses





    2,700,000







    2,700,000



    Total Current Assets





    18,039,365







    10,968,878





















    Other Assets:

















    In-process research and development





    73,400,000







    73,400,000



    Total Other Assets





    73,400,000







    73,400,000





















    Total Assets



    $

    91,439,365





    $

    84,368,878



    LIABILITIES AND STOCKHOLDERS' EQUITY

















    Current Liabilities:

















    Accounts payable



    $

    7,676,310





    $

    3,711,622



    License payable





    28,400,000







    28,400,000



    Accrued expenses





    8,722,168







    —



    Due to related party





    4,941,664







    588,806



    Total Current Liabilities





    49,740,142







    32,700,428





















    Deferred tax liability





    2,256,480







    1,728,000



    Note payable to related party





    3,800,111







    3,800,111



    Total Liabilities





    55,796,733







    38,228,539



    Stockholders' Equity:

















    Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued

       and outstanding





    —







    —



    Common stock - $0.0001 par value; 100,000,000; 71,552,402 shares issued and

       outstanding at March 31, 2025 and September 30, 2024





    7,155







    7,155



    Additional paid-in capital





    89,308,821







    85,411,771



    Accumulated deficit





    (53,673,344)







    (39,278,587)



    Total Stockholders' Equity





    35,642,632







    46,140,339



    Total Liabilities and Stockholders' Equity



    $

    91,439,365





    $

    84,368,878



     

    CITIUS ONCOLOGY, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2025 AND 2024

    (Unaudited)



















    Three Months Ended





    Six Months Ended







    March 31,





    March 31,





    March 31,





    March 31,







    2025





    2024





    2025





    2024



    Revenues



    $

    —





    $

    —





    $

    —





    $

    —





































    Operating Expenses

































    Research and development





    3,139,413







    1,348,966







    4,403,921







    2,497,461



    General and administrative





    2,243,327







    1,385,580







    5,565,306







    2,903,488



    Stock-based compensation – general and administrative





    2,088,572







    1,957,000







    3,897,050







    3,874,000



    Total Operating Expenses





    7,471,312







    4,691,546







    13,866,277







    9,274,949





































    Loss before Income Taxes





    (7,471,312)







    (4,691,546)







    (13,866,277)







    (9,274,949)



    Income tax expense





    264,240







    144,000







    528,480







    288,000





































    Net Loss



    $

    (7,735,552)





    $

    (4,835,546)





    $

    (14,394,757)





    $

    (9,562,949)





































    Net Loss Per Share - Basic and Diluted



    $

    (0.11)





    $

    (0.07)





    $

    (0.20)





    $

    (0.14)





































    Weighted Average Common Shares Outstanding

































    Basic and diluted





    71,552,402







    67,500,000







    71,552,402







    67,500,000



     

    CITIUS ONCOLOGY, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    FOR THE SIX MONTHS ENDED MARCH 31, 2025 AND 2024

    (Unaudited)



















    2025





    2024



    Cash Flows From Operating Activities:

















    Net loss



    $

    (14,394,757)





    $

    (9,562,949)



    Adjustments to reconcile net loss to net cash provided by operating activities:

















       Stock-based compensation expense





    3,897,050







    3,874,000



       Deferred income tax expense





    528,480







    288,000



    Changes in operating assets and liabilities:

















       Inventory





    (7,070,487)











       Prepaid expenses













    (1,171,920)



       Accounts payable





    3,964,688







    (785,132)



       Accrued expenses





    8,722,168







    (259,071)



       Due to related party





    4,352,858







    7,617,072



    Net Cash Provided By Operating Activities





    -







    -





















    Net Change in Cash and Cash Equivalents





    -







    -



    Cash and Cash Equivalents – Beginning of Period





    112







    -



    Cash and Cash Equivalents – End of Period



    $

    112





    $

    -



     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-oncology-inc-reports-fiscal-second-quarter-2025-financial-results-and-provides-business-update-302455668.html

    SOURCE Citius Oncology, Inc.

    Get the next $CTOR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CTOR

    DatePrice TargetRatingAnalyst
    11/27/2024$3.00Buy
    Maxim Group
    More analyst ratings

    $CTOR
    SEC Filings

    See more
    • Citius Oncology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

      7/18/25 8:01:46 AM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Citius Oncology Inc.

      EFFECT - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

      7/17/25 12:15:15 AM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B4 filed by Citius Oncology Inc.

      424B4 - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

      7/16/25 9:21:46 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Mayersohn Joel David

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      12/16/24 5:05:14 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Holuka Eugene Myron

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      12/16/24 4:09:27 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Secretary Holubiak Myron Z

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      12/16/24 4:09:06 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Citius Oncology Announces Closing of $9.0 Million Public Offering

      CRANFORD, N.J., July 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), today announced the closing of its "reasonable best-efforts" public offering of 6,818,182 shares of common stock of the Company and warrants to purchase shares of common stock at a public offering price of $1.32 per share. The warrants have an exercise price of $1.32 per share, are immediately exercisable upon issuance, and expire five years from the date of issuance. Gross proceeds from the offering, before deducting placement agent fees and other estimated offering expenses, are approximately $9.0

      7/17/25 4:30:00 PM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Oncology Announces Pricing of $9.0 Million Public Offering

      CRANFORD, N.J., July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), today announced the pricing of its "reasonable best-efforts" public offering of 6,818,182 shares of common stock of the Company and warrants to purchase shares of common stock at a public offering price of $1.32 per share. The warrants will have an exercise price of $1.32 per share, will be immediately exercisable upon issuance, and will expire five years from the date of issuance. Gross proceeds from the offering, before deducting placement agent fees and other estimated offering expenses, are expec

      7/16/25 9:15:00 AM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

      Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™ CRANFORD, N.J., July 15, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), today announced the execution of a distribution services agreement with Cencora (formerly AmerisourceBergen), a global pharmaceutical services company. This agreement marks another significant step forward in the Company's commercial launch strategy for LYMPHIR (denileukin diftitox-cxdl), its FDA-approved immunotherapy for relapsed or refractory cutaneous T

      7/15/25 8:32:00 AM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Citius Oncology with a new price target

      Maxim Group initiated coverage of Citius Oncology with a rating of Buy and set a new price target of $3.00

      11/27/24 8:17:22 AM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTOR
    Leadership Updates

    Live Leadership Updates

    See more
    • Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

      Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo

      7/8/25 10:25:00 AM ET
      $CELC
      $CTOR
      $EXEL
      $ONCY
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

      6/26/25 11:44:00 AM ET
      $ADCT
      $CTOR
      $ONCY
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • After Major Oncology Conference, All Eyes Turn to Industry Innovation

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

      6/12/25 9:00:00 AM ET
      $CAH
      $CTOR
      $CTXR
      $ONCY
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CTOR
    Financials

    Live finance-specific insights

    See more
    • Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

      Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL);Advanced ma

      12/27/24 5:00:00 PM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Citius Oncology Inc.

      SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      11/6/24 5:08:07 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Citius Oncology Inc.

      SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      9/5/24 9:23:54 AM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Citius Oncology Inc.

      SC 13D - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      8/16/24 4:34:29 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care